Increased use of EHR leads to increased debate over patients’ rights
INDIANAPOLIS The debate over patients’ control of their health records is increasing as more providers adopt electronic health records.
More than a month ago, the National Committee on Vital and Health Statistics sent a letter to the Department of Health and Human Services recommending that patients have the power to withhold certain sensitive information from EHRs, such as reproductive health or genetic information.
One of the concerns the NCVHS has with EHR’s is that, employers and insurance companies could access the patients’ records and use the information against them.
Marc Overhage, chief executive officer of the Indiana Health Information Exchange had a different opinion. He noted that physicians need access to personal information to provide the best care possible. He also stated that to implement those kinds of initiatives would cost hundreds of millions of dollars.
Arcadia funds DailyMed with $5 million debt facility
INDIANPOLIS Arcadia Resources, a provider of consumer health services doing business under the trade name of Arcadia HealthCare, has obtained a new $5 million debt facility to fund the growth of DailyMed and its related pharmacy fulfillment strategy.
DailyMed, which launched April 2006, is a retail drug packaging solution that pre-sorts multiple prescriptions, OTC medications and vitamins into easy-to-use single-dose packets.
“The financing will provide Arcadia with the cash to fund DailyMed and our related pharmacy fulfillment strategy and the working capital needs associated with the pharmacy business growth anticipated during our fiscal year beginning April 1, 2008,” stated Marvin Richardson, president and chief executive officer. “This deal represents an important first step towards executing our fiscal 2009 growth strategy and is significant in that the majority of debt will be used to grow our DailyMed business rather than meet core operating cash obligations.”
The facility matures on Oct. 31, 2009, bears interest at an annual rate of 10 percent and is secured by certain company assets.
FDA approves Sun’s generic Tessalon
WASHINGTON Sun has received FDA approval for a generic version of Forest Laboratories’ Tessalon capsules, a treatment for coughs due to the common cold, pneumonia and other lung infections.
The company, a week ago, also announced it had received FDA approval for its generic version of Pfizer’s Cerebyx (fosphenytoin sodium), an injectable anticonvulsant that has annual U.S. sales of approximately $15 million.
Brand and generic Tessalon (benzonatate) have annual U.S. sales of approximately $40 million, according to Sun.